Cholangiocytic Originated Liver Tumour (COLT) Alliance
Research type
Research Study
Full title
Reassessment of combined Hepatocellular-Cholangiocarcinoma (cHCC-CCA) and intrahepatic Cholangiocarcinoma (iCCA) According to the New (2019) Histopathological Classification of the World Health Organization (WHO)
IRAS ID
310628
Contact name
Alberto Quaglia
Contact email
Sponsor organisation
Royal Free London
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
This study is an international multicentre study lead by Venancio Alves, Professor of Pathology, Sao Paulo Brazil and Dr Marco Claasen a surgeon from Toronto, Canada, entitled "Reassessment of hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma (cHCC-CCA and iCCA) According to the New (2019) Histopathological Classification of the World Health Organization (WHO)".
The purpose of the study is to find out whether the new WHO classification of liver tumours has an impact on prognosis.
The study consists in selecting from each institution all possible informative cases (i.e. livers removed at transplantation and containing the following types of liver tumours: intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma) in the last 10 years. The representative histology glass slides (i.e. those of the samples taken from the resection specimen for diagnostic purposes) of each tumour will be anonymised and digitalized using a slide scanner. The anonymised digitalised histological images will be uploaded on the PathPresenter digital platform. All metadata will be removed, and no centres will be able to download the digitalised slides. Once all cases from all participating centres are uploaded, an international panel of liver pathologists (including myself) will review all cases and classify them according to the latest WHO classification.
The histological diagnosis will then be correlated with anonymised outcome data provided by the participating clinicians from each centre. Professor Brian Davidson is the participating clinician from the Royal Free and has already received ethical approval (please see section A5-2).REC name
HSC REC A
REC reference
22/NI/0153
Date of REC Opinion
26 Sep 2022
REC opinion
Further Information Favourable Opinion